Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.81 |
| ▸ | ERBB3 | P21860 | 3/20 | 0.67 |
| ▸ | DUS2 | Q9NX74 | 1/20 | 0.67 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.66 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.66 |
| ▸ | KIT | P10721 | 2/20 | 0.66 |
| ▸ | SRC | P12931 | 2/20 | 0.66 |
| ▸ | KDR | P35968 | 2/20 | 0.66 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.66 |
| ▸ | CIT | O14578 | 1/20 | 0.66 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.66 |
| ▸ | GAK | O14976 | 1/20 | 0.66 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.66 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.66 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.66 |
| ▸ | STK17B | O94768 | 1/20 | 0.66 |
| ▸ | STK10 | O94804 | 1/20 | 0.66 |
| ▸ | ABL1 | P00519 | 1/20 | 0.66 |
| ▸ | LCK | P06239 | 1/20 | 0.66 |
| ▸ | FYN | P06241 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15090536 | 0.96 | EGFR (0.87) | EGFRERBB3DUS2ERBB4ERBB2 | |
| SCHEMBL15090618 | 0.89 | EGFR (1.00) | EGFRERBB3DUS2ERBB4ERBB2 | |
| SCHEMBL15090523 | 0.88 | EGFR (1.00) | EGFRERBB3DUS2ERBB4ERBB2 | |
| SCHEMBL15090537 | 0.85 | EGFR (1.00) | EGFRERBB3DUS2ERBB4ERBB2 | |
| SCHEMBL255508 | 0.85 | EGFR (1.00) | EGFRERBB3DUS2ERBB4ERBB2 | |
| SCHEMBL18595943 | 0.85 | EGFR (0.76) | EGFRERBB4ERBB2SRCGAK | |
| SCHEMBL15106854 | 0.84 | EGFR (0.58) | EGFRERBB2KDRPDGFRBEPHB4 | |
| SCHEMBL15781132 | 0.84 | EGFR (0.67) | EGFRERBB4ERBB2SRCGAK | |
| SCHEMBL18862908 | 0.84 | EGFR (0.68) | EGFRERBB4ERBB2KDREPHB4 | |
| SCHEMBL15090691 | 0.84 | EGFR (1.00) | EGFRERBB3DUS2ERBB4ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10507209-B2 | Quinazoline derivatives substituted by aniline, preparation method and use thereof | XUANZHU PHARMA CO, LTD. (CN) | 2019-12-17 | — | — | US | claimed |
| US-20170333433-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | XUANZHU PHARMA CO, LTD. (CN) | 2017-11-23 | — | — | US | claimed |
| US-20170304305-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | XUANZHU PHARMA CO LTD (CN) | 2017-10-26 | — | — | US | claimed |
| US-9730934-B2 | Quinazoline derivatives substituted by aniline, preparation method and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-08-15 | — | — | US | claimed |
| EP-2612860-B1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | XUANZHU PHARMA CO LTD (CN) | 2017-03-15 | — | — | EP | claimed |
| US-20130184297-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2013-07-18 | — | — | US | claimed |
| EP-2612860-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2013-07-10 | — | — | EP | claimed |
| US-10507209-B2 | Quinazoline derivatives substituted by aniline, preparation method and use thereof | XUANZHU PHARMA CO, LTD. (CN) | 2019-12-17 | — | — | US | disclosed |
| US-10507209-B2 | Quinazoline derivatives substituted by aniline, preparation method and use thereof | XUANZHU PHARMA CO, LTD. (CN) | 2019-12-17 | — | — | US | disclosed |
| US-20170333433-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | XUANZHU PHARMA CO, LTD. (CN) | 2017-11-23 | — | — | US | disclosed |
| US-20170333433-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | XUANZHU PHARMA CO, LTD. (CN) | 2017-11-23 | — | — | US | disclosed |
| US-20170333433-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | XUANZHU PHARMA CO, LTD. (CN) | 2017-11-23 | — | — | US | disclosed |
| US-20170304305-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | XUANZHU PHARMA CO LTD (CN) | 2017-10-26 | — | — | US | disclosed |
| US-9730934-B2 | Quinazoline derivatives substituted by aniline, preparation method and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-08-15 | — | — | US | disclosed |
| EP-2612860-B1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | XUANZHU PHARMA CO LTD (CN) | 2017-03-15 | — | — | EP | disclosed |
| EP-2612860-B1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | XUANZHU PHARMA CO LTD (CN) | 2017-03-15 | — | — | EP | disclosed |
| US-20130184297-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2013-07-18 | — | — | US | disclosed |
| US-20130184297-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2013-07-18 | — | — | US | disclosed |
| US-20130184297-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2013-07-18 | — | — | US | disclosed |
| EP-2612860-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2013-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304305-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | NQO2, CHRM1, CHRM2 | EGFR 983/4885ERBB3 1406/4885DUS2 1789/4885 |
| US-20170333433-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | NQO2, CHRM1, CHRM2 | EGFR 983/4885ERBB3 1406/4885DUS2 1789/4885 |
| US-10507209-B2 | Quinazoline derivatives substituted by aniline, preparation method and use thereof | NQO2, CHRM1, CHRM2 | EGFR 983/4885ERBB3 1406/4885DUS2 1789/4885 |
| US-20130184297-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | NQO2, CHRM1, CHRM2 | EGFR 983/4885ERBB3 1406/4885DUS2 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.